NovoCure: Why I’m Fading The Q2 Earnings Rally (NASDAQ:NVCR)
· seekingalpha.com
NovoCure stock remains a Hold: Q2 revenue rose 16% and EBITDA guidance improved, but cash generation lags. Click to read my analysis.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...